Filing Details
- Accession Number:
- 0001127602-24-020307
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-11 18:41:06
- Reporting Period:
- 2024-07-09
- Accepted Time:
- 2024-07-11 18:41:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1326732 | Xencor Inc | XNCR | Pharmaceutical Preparations (2834) | 201622502 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1591313 | R John Desjarlais | C/O Xencor, Inc. 465 N Halstead Street, Suite 200 Pasadena CA 91107 | Sr. Vice President & Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-09 | 42,215 | $10.73 | 228,648 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-09 | 36,329 | $18.32 | 192,319 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-07-10 | 7,785 | $10.73 | 200,104 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-07-09 | 42,215 | $0.00 | 42,215 | $10.73 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-07-10 | 7,785 | $0.00 | 7,785 | $10.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,785 | 2024-07-13 | No | 4 | M | Direct | |
| 0 | 2024-07-13 | No | 4 | M | Direct |
Footnotes
- This transaction is pursuant to a 10b5-1 plan.
- Underlying option due to expire in July 2024.
- Represents the disposition of shares sold to pay option cost and estimated tax liability due upon option exercise.
- 25% of the shares subject to the option shall vest on the one year anniversary of July 14, 2014 (the "Vesting Commencement Date"), and 1/48th of the shares shall vest monthly thereafter, such that the option shall be fully vested and exercisable on the four year anniversary of the Vesting Commencement Date.
Billionaire Hedge Funds
